Patent ID: 7794934

Claim:
A method of identifying a human schizophrenic subject having a propensity to respond to clozapine drug therapy, comprising: a) isolating genomic DNA from a sample of the subject; b) genotyping a T5988C marker of a GRIN2B gene; and c) identifying the propensity said human schizophrenic subject to respond to clozapine drug therapy based on said genotyping of the T5988C marker of the GRIN2B gene; wherein a GRIN2B 5988 T/T genotype identifies the human schizophrenic subject as having a higher propensity to respond to clozapine drug therapy, relative to a GRIN2B 5988 C/C genotype or a GRIN2B 5988 C/T genotype, and wherein responding to clozapine drug therapy comprises an improvement in negative symptoms selected from the group consisting of the range and intensity of emotional expression, affective flattening, anhedonia, social withdrawal, restriction in the fluency and productivity of thought and speech, alogia, restriction in the initiation of goal-directed behavior, avolition, lack of interest in activities, or a combination thereof.